NCT00360360 - Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2009

Conditions

Neoplasm, Unknown Primary

Interventions

DRUG

paclitaxel

Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1

DRUG

carboplatin

Carboplatin AUC 6.0 IV Day 1

DRUG

bevacizumab

Bevacizumab 15mg/kg IV infusion,Day 1

DRUG

erlotinib

Erlotinib 150 mg by mouth daily

Trial Locations (9)

Spartanburg Regional Medical Center, Spartanburg

Northeast Georgia Medical Center, Gainesville

Integrated Community Oncology Network, Jacksonville

Tennessee Oncology, PLLC, Nashville

Chattanooga Oncology Hematology Associates, Chattanooga

Graves-Gilbert Clinic, Bowling Green

Oncology Hematology Care, Cincinnati

Oncology Hematology Associates of SW Indiana, Evansville

Baton Rouge General Medical Center, Baton Rouge